This is underlined by a study published by the Medicines Agency.
Article written by
Posted
Reading time : 1 min.
Messenger RNA vaccines against Covid-19 do not increase the risk of serious cardiovascular problems (heart attack, stroke or pulmonary embolism) in people under 75. This is underlined by a study published Tuesday, January 18 by the Medicines Agency.
As part of the enhanced vaccine monitoring system, Epi-Phare, a structure associating Health Insurance (Cnam) and the Medicines Agency (ANSM), conducted a study on the risk of serious cardiovascular event (excluding myocarditis and pericarditis) within three weeks of injection of an mRNA or adenovirus vaccine.
This study focused on all adults aged 18 to 74, vaccinated or not, admitted to hospital in France between December 27, 2020 and July 20, 2021 for acute myocardial infarction, ischemic stroke or haemorrhagic, or pulmonary embolism.
His results confirm the “safety of mRNA vaccines” (those of Pfizer and Moderna) “As regards the risk of a serious cardiovascular event in adults” which could have occurred within three weeks of the first or second dose of the vaccines.
In contrast, adenovirus vaccines (those from AstraZeneca and Janssen) appear “associated with a small increased risk of myocardial infarction and pulmonary embolism in adults within two weeks of injection”. These adenovirus vaccines are little used in France, recalls the ANSM.